TY - JOUR
T1 - Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD
T2 - Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study
AU - CRIC Study Investigators
AU - Zhan, Min
AU - Doerfler, Rebecca M.
AU - Xie, Dawei
AU - Chen, Jing
AU - Chen, Hsiang Yu
AU - Diamantidis, Clarissa J.
AU - Rahman, Mahboob
AU - Ricardo, Ana C.
AU - Sondheimer, James
AU - Strauss, Louise
AU - Wagner, Lee Ann
AU - Weir, Matthew R.
AU - Fink, Jeffrey C.
AU - Appel, Lawrence J.
AU - Feldman, Harold I.
AU - Go, Alan S.
AU - He, Jiang
AU - Kusek, John W.
AU - Lash, James P.
AU - Rao, Panduranga S.
AU - Townsend, Raymond R.
N1 - Funding Information:
Drs Fink, Doerfler, and Zhan were supported by National Institutes of Health (NIH)/ National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK090008 . Funding for the CRIC Study was obtained under a cooperative agreement from NIDDK ( U01DK060990 , U01DK060984 , U01DK061022 , U01DK061021 , U01DK061028 , U01DK060980 , U01DK060963 , and U01DK060902 ). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award (CTSA) NIH/ National Center for Advancing Translational Sciences (NCATS) UL1TR000003 , Johns Hopkins University UL1 TR-000424 , University of Maryland GCRC M01 RR-16500 , Clinical and Translational Science Collaborative of Cleveland , UL1TR000439 from the NCATS component of the NIH and NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) V 2014.07.28 UL1TR000433 , University of Illinois at Chicago CTSA UL1RR029879 , Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036 , Kaiser Permanente NIH/ National Center for Research Resources UCSF-CTSI UL1 RR-024131 . The funders did not have a role in study design; data collection, analysis, or reporting; or the decision to submit for publication.
Funding Information:
Lawrence J. Appel, MD, MPH, Harold I. Feldman, MD, MSCE, Alan S. Go, MD, Jiang He MD, PhD, John W. Kusek, PhD, James P. Lash, MD, Panduranga S. Rao, MD, Mahboob Rahman, MD, and Raymond R. Townsend, MD. Min Zhan, PhD, Rebecca M. Doerfler, PhD, Dawei Xie, PhD, Jing Chen, MD, Hsiang-Yu Chen, MS, Clarissa J. Diamantidis, MD, Mahboob Rahman, MD, Ana C. Ricardo, MD, James Sondheimer, MD, Louise Strauss, BSN, Lee-Ann Wagner, MD, Matthew R. Weir, MD, and Jeffrey C. Fink, MD, MS. Research idea and study design: MZ, JCF; data acquisition: DX, HYC; data analysis/interpretation: MZ, MR, ACR, JS, LS, L-AW, JCF; data curation: RMD, JCF; data visualization: RMD, JCF, JC; statistical analysis: MZ; supervision or mentorship: CJD, MRW. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. Drs Fink, Doerfler, and Zhan were supported by National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK090008. Funding for the CRIC Study was obtained under a cooperative agreement from NIDDK (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award (CTSA) NIH/National Center for Advancing Translational Sciences (NCATS) UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical and Translational Science Collaborative of Cleveland, UL1TR000439 from the NCATS component of the NIH and NIH Roadmap for Medical Research, Michigan Institute for Clinical and Health Research (MICHR) V 2014.07.28 UL1TR000433, University of Illinois at Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases P20 GM109036, Kaiser Permanente NIH/National Center for Research Resources UCSF-CTSI UL1 RR-024131. The funders did not have a role in study design; data collection, analysis, or reporting; or the decision to submit for publication. The authors declare that they have no relevant financial interests. Received July 5, 2019. Evaluated by 3 external peer reviewers and a statistician, with editorial input from an Acting Editor-in-Chief (Editorial Board Member Jane Schell, MD). Accepted in revised form December 11, 2019. The involvement of an Acting Editor-in-Chief to handle the peer-review and decision-making processes was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.
Publisher Copyright:
© 2020 The Authors
PY - 2020/8
Y1 - 2020/8
N2 - Rationale & Objective: Safe analgesic choices are limited in chronic kidney disease (CKD). We conducted a comparative analysis of harm from opioids versus nonsteroidal anti-inflammatory drugs (NSAIDs) in CKD. Study Design: Prospective cohort study. Setting & Participants: 3,939 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. Exposures: 30-day analgesic use reported at annual visits. Outcomes: A composite outcome of 50% glomerular filtration rate reduction and kidney failure requiring kidney replacement therapy (KRT), as well as the outcomes of kidney failure requiring KRT, hospitalization, and pre–kidney failure death. Analytical Approach: Marginal structural models with time-updated exposures. Results: Participants were followed up for a median of 6.84 years, with 391 (9.9%) and 612 (15.5%) reporting baseline opioid and NSAID use, respectively. Time-updated opioid use was associated with the kidney disease composite outcome, kidney failure with KRT, death (HRs of 1.4 [95% CI, 1.2-1.7], 1.4 [95% CI, 1.1-1.7], and 1.5 [95% CI, 1.2-2.0], respectively), and hospitalization (rate ratio [RR], 1.7; 95% CI, 1.6-1.9) versus opioid nonusers. Similar results were found in an analysis restricted to a subcohort of participants reporting ever using other (nonopioid and non-NSAID) analgesics or tramadol. Time-updated NSAID use was associated with increased risk for the kidney disease composite (HR, 1.2; 95% CI, 1.0-1.5) and hospitalization (RR, 1.1; 95% CI, 1.0-1.3); however, these associations were not significant in the subcohort. The association of NSAID use with the kidney disease composite outcome varied by race, with a significant risk in blacks (HR, 1.3; 95% CI, 1.0-1.7). NSAID use was associated with lower risk for kidney failure with KRT in women and individuals with glomerular filtration rate < 45 mL/min/1.73 m2 (HRs of 0.63 [95% CI, 0.45-0.88] and 0.77 [95% CI, 0.59-0.99], respectively). Limitations: Limited periods of recall of analgesic use and potential confounding by indication. Conclusions: Opioid use had a stronger association with adverse events than NSAIDs, with the latter's association with kidney disease outcomes limited to specific subgroups, notably those of black race.
AB - Rationale & Objective: Safe analgesic choices are limited in chronic kidney disease (CKD). We conducted a comparative analysis of harm from opioids versus nonsteroidal anti-inflammatory drugs (NSAIDs) in CKD. Study Design: Prospective cohort study. Setting & Participants: 3,939 patients with CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study. Exposures: 30-day analgesic use reported at annual visits. Outcomes: A composite outcome of 50% glomerular filtration rate reduction and kidney failure requiring kidney replacement therapy (KRT), as well as the outcomes of kidney failure requiring KRT, hospitalization, and pre–kidney failure death. Analytical Approach: Marginal structural models with time-updated exposures. Results: Participants were followed up for a median of 6.84 years, with 391 (9.9%) and 612 (15.5%) reporting baseline opioid and NSAID use, respectively. Time-updated opioid use was associated with the kidney disease composite outcome, kidney failure with KRT, death (HRs of 1.4 [95% CI, 1.2-1.7], 1.4 [95% CI, 1.1-1.7], and 1.5 [95% CI, 1.2-2.0], respectively), and hospitalization (rate ratio [RR], 1.7; 95% CI, 1.6-1.9) versus opioid nonusers. Similar results were found in an analysis restricted to a subcohort of participants reporting ever using other (nonopioid and non-NSAID) analgesics or tramadol. Time-updated NSAID use was associated with increased risk for the kidney disease composite (HR, 1.2; 95% CI, 1.0-1.5) and hospitalization (RR, 1.1; 95% CI, 1.0-1.3); however, these associations were not significant in the subcohort. The association of NSAID use with the kidney disease composite outcome varied by race, with a significant risk in blacks (HR, 1.3; 95% CI, 1.0-1.7). NSAID use was associated with lower risk for kidney failure with KRT in women and individuals with glomerular filtration rate < 45 mL/min/1.73 m2 (HRs of 0.63 [95% CI, 0.45-0.88] and 0.77 [95% CI, 0.59-0.99], respectively). Limitations: Limited periods of recall of analgesic use and potential confounding by indication. Conclusions: Opioid use had a stronger association with adverse events than NSAIDs, with the latter's association with kidney disease outcomes limited to specific subgroups, notably those of black race.
KW - COX-2 inhibitor
KW - Chronic kidney disease (CKD)
KW - analgesics
KW - drug safety
KW - end-stage renal disease (ESRD)
KW - kidney disease progression
KW - kidney function
KW - non-steroidal anti-inflammatory drug (NSAID)
KW - opioids
KW - outcomes
KW - pain management
UR - http://www.scopus.com/inward/record.url?scp=85083338392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083338392&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2019.12.010
DO - 10.1053/j.ajkd.2019.12.010
M3 - Article
C2 - 32317121
AN - SCOPUS:85083338392
SN - 0272-6386
VL - 76
SP - 184
EP - 193
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 2
ER -